<DOC>
	<DOCNO>NCT00267553</DOCNO>
	<brief_summary>Protocol 777-CLP-32 treatment survival continuation protocol Biomed 777-CLP-29 , continue compare combine hormonal therapy use experimental aromatase inhibitor ( AI ) atamestane combine FDA-approved anti-estrogen toremifene ( Fareston® ) , single agent FDA-approved aromatase inhibitor letrozole ( Femara® ) treatment advance breast cancer . The purpose study determine whether maximal estrogen suppression achieve via combination atamestane , plus toremifene ( Fareston® ) , effective letrozole ( Femara® ) delay growth breast cancer .</brief_summary>
	<brief_title>Treatment Survival Continuation Study Atamestane Plus Toremifene vs Letrozole Advanced Breast Cancer</brief_title>
	<detailed_description>Aromatase enzyme express tissue muscle fat postmenopausal woman . These non-ovarian tissue become dominant source estrogen postmenopausal woman . Breast cancer cell often dependent estrogen continue grow . Atamestane block formation estrogens androgenic precursor body via aromatase enzyme . Toremifene block circulate intracellular estrogen stimulate estrogen receptor breast cancer cell . The goal therapy atamestane , aromatase inhibitor , combination estrogen receptor antagonist , toremifene , achieve complete suppression estrogen stimulation breast cancer cell . This study design determine whether combined hormonal therapy lengthen time disease progression survival time subject advance breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Hormone-Dependent</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Atamestane</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>To eligible receive continue treatment , subject must remain eligible receive study drug time last Biomed 777CLP29 visit To continue survival followup , subject must survival followup study Biomed 777CLP29 Written inform consent obtain subject continue study drug treatment Subjects withdrawn consent participate Biomed 777CLP29 reason Subjects investigator considers study participation longer best interest subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Atamestane</keyword>
	<keyword>Breast neoplasm</keyword>
	<keyword>Combined hormonal therapy</keyword>
	<keyword>Complete estrogen blockade</keyword>
	<keyword>Ductal breast carcinoma</keyword>
	<keyword>Estrogen blocker</keyword>
	<keyword>Fareston®</keyword>
	<keyword>Femara®</keyword>
	<keyword>First line therapy</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Lobular breast carcinoma</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Locally recurrent breast cancer</keyword>
	<keyword>Maximal estrogen inhibition</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Neoplasms , Hormone-dependent</keyword>
	<keyword>Receptor-positive</keyword>
	<keyword>Stage IIIA breast cancer</keyword>
	<keyword>Stage IIIB breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>Toremifene</keyword>
</DOC>